623559-03-5

Usage

General Description

[4-(3-morpholin-4-yl-propoxy)phenyl]carbamic acid tert-butyl ester, also known as tBoc-Lys(Fmoc)-OH, is a chemical compound commonly used in organic synthesis and peptide chemistry. It is a derivative of carbamic acid and contains a tert-butyl ester functional group. The presence of the phenyl and morpholin-4-yl-propoxy moieties makes it useful as a building block for the synthesis of various organic compounds. It is commonly used as a protecting group in peptide synthesis to temporarily block the reactive amine group of lysine, allowing for selective reactions to occur at other functional groups within the peptide chain. Additionally, it can be used as a reagent in organic transformations and as a starting material for the synthesis of pharmaceutical compounds.

Upstream product

• 4441-30-9 3-morpholin-4-ylpropan-1-ol 
• 110-91-8 morpholine 
• 54840-15-2 4-N-tert-butoxycarbonylaminophenol 
• 1018895-28-7 methanesulfonic acid 3-morpholin-4-yl-propyl ester 

Downstream Products

• 100800-40-6 4-[3-(morpholin-4-yl)propoxy]aniline 
• 1061377-71-6 1-cyclohexyl-3-[4-(3-morpholin-4-yl-propoxy)phenyl]urea 
• 1061377-73-8 2-adamantan-1-yl-N-[4-(3-morpholin-4-yl-propoxy)phenyl]acetamide 

Relevant academic research and scientific papers

4-Aminoquinoline derivatives as novel Mycobacterium tuberculosis GyrB inhibitors: Structural optimization, synthesis and biological evaluation

Mycobacterial DNA gyrase B subunit has been identified to be one of the potentially underexploited drug targets in the field of antitubercular drug discovery. In the present study, we employed structural optimization of the reported GyrB inhibitor resulting in synthesis of a series of 46 novel quinoline derivatives. The compounds were evaluated for their in vitro Mycobacterium smegmatis GyrB inhibitory ability and Mycobacterium tuberculosis DNA supercoiling inhibitory activity. The antitubercular activity of these compounds was tested over Mtb H37Rv strain and their safety profile was checked against mouse macrophage RAW 264.7 cell line. Among all, three compounds (23, 28, and 53) emerged to be active displaying IC50 values below 1 μM against Msm GyrB and were found to be non-cytotoxic at 50 μM concentration. Compound 53 was identified to be potent GyrB inhibitor with 0.86 ± 0.16 μM and an MIC (minimum inhibitory concentration) of 3.3 μM. The binding affinity of this compound towards GyrB protein was analysed by differential scanning fluorimetry which resulted in a positive shift of 3.3 °C in melting temperature (Tm) when compared to the native protein thereby reacertaining the stabilization effect of the compound over protein.

Unsymmetrical non-adamantyl N,N′-diaryl urea and amide inhibitors of soluble expoxide hydrolase

Incorporation of an adamantyl group in prototypical soluble expoxide hydrolase (sEH) inhibitors afforded improved enzyme potency. We explored replacement of the adamantyl group in unsymmetrical ureas and amides with substituted aryl rings to identify equipotent and metabolically stable sEH inhibitors. We found that aryl rings, especially those substituted in the para position with a strongly electron withdrawing substituent, afforded enzyme IC50 values comparable to the adamantyl compounds in an ether substituted, unsymmetrical N,N′-diaryl urea or amide scaffold.

SOLUBLE EPOXIDE HYDROLASE INHIBITORS

Disclosed are urea and thiourea compounds and compositions that inhibit soluble epoxide hydrolase (sEH), methods for preparing the compounds and compositions, and methods for treating patients with such compounds and compositions. The compounds, compositions, and methods are useful for treating a variety of sEH mediated diseases, including hypertensive, cardiovascular, inflammatory, and diabetic-related diseases.